
Elvina Almuradova and Komal Jhaveri
Apr 9, 2025, 08:51
Elvina Almuradova: Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Elvina Almuradova, Ambassador at European School of Oncology, shared an article Komal Jhaveri and her colleagues authored on X:
“New in NEJM!!!
Imlunestrant shows promise in ER+/HER2- advanced breast cancer with ESR1 mutations – PFS 5.5 vs 3.8 months vs standard therapy. Adding Abemaciclib boosts PFS to 9.4 months.”
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Authors: Komal L. Jhaveri et al.
Imlunestrant and Abemaciclib: A Study in Advanced Breast Cancer
André Mattar
Antonio Llombart-Cussac
Breast Cancer
cancer
Chih-Chiang Hung
Chiun-Sheng Huang
Christoph Cramer von Laue
Cristina Saura
Elgene Lim
Emily Barrett
Eriko Tokunaga
François-Clément Bidard
Giuseppe Curigliano
Joohyuk Sohn
Jorge Luis Martinez Rodriguez
Joyce O'Shaughnessy
Kamnesh R. Pradhan
Komal L. Jhaveri
Lillian M. Smyth
Lisa A. Carey
Manuel Ruiz Borrego
María de la Luz García Tinoco
Monica Lis Casalnuovo
Nadia Harbeck
OncoDaily
Oncology
Patrick Neven
Philippe Aftimos
Qingyuan Zhang
Rikiya Nakamura
Shanshan Cao
Sung-Bae Kim
Xuejing Aimee Wang
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 14, 2025, 13:49
Apr 14, 2025, 13:47
Apr 14, 2025, 13:40
Apr 14, 2025, 13:36
Apr 14, 2025, 13:31
Apr 14, 2025, 13:19
Apr 14, 2025, 12:43